The [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) (UPS) is the primary cellular machinery for targeted protein degradation, responsible for removing misfolded, oxidized, and regulatory proteins. In Parkinson's disease, UPS dysfunction plays a central role in the accumulation of pathogenic proteins like [alpha-synuclein](/proteins/alpha-synuclein) and [LRRK2](/proteins/lrrk2-protein), contributing to neuronal death [@cookson2015]. First described in the early 2000s, UPS impairment is now recognized as a fundamental pathological mechanism underlying both familial and sporadic forms of Parkinson's disease (PD) [@mcnaught2001].
The ubiquitin-proteasome system represents the major ATP-dependent protein degradation pathway in eukaryotic cells, responsible for degrading approximately 80-90% of all intracellular proteins. This system maintains cellular proteostasis by eliminating misfolded proteins, regulatory proteins, and damaged organelles. In PD, genetic mutations affecting UPS components, environmental toxins, and age-related declines in proteasome activity converge to impair protein clearance, leading to the accumulation of toxic protein aggregates that characterize the disease [@burchell2013].
The [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) (UPS) is the primary cellular machinery for targeted protein degradation, responsible for removing misfolded, oxidized, and regulatory proteins. In Parkinson's disease, UPS dysfunction plays a central role in the accumulation of pathogenic proteins like [alpha-synuclein](/proteins/alpha-synuclein) and [LRRK2](/proteins/lrrk2-protein), contributing to neuronal death [@cookson2015]. First described in the early 2000s, UPS impairment is now recognized as a fundamental pathological mechanism underlying both familial and sporadic forms of Parkinson's disease (PD) [@mcnaught2001].
The ubiquitin-proteasome system represents the major ATP-dependent protein degradation pathway in eukaryotic cells, responsible for degrading approximately 80-90% of all intracellular proteins. This system maintains cellular proteostasis by eliminating misfolded proteins, regulatory proteins, and damaged organelles. In PD, genetic mutations affecting UPS components, environmental toxins, and age-related declines in proteasome activity converge to impair protein clearance, leading to the accumulation of toxic protein aggregates that characterize the disease [@burchell2013].
The connection between UPS dysfunction and Parkinson's disease was first established through genetic studies identifying mutations in genes encoding UPS components. The discovery of [PARK2/parkin](/genes/parkin) mutations causing juvenile-onset Parkinson's disease in 1998 represented a watershed moment in understanding the role of protein degradation in neurodegeneration [@dawson2004]. Subsequent identification of [PINK1](/genes/pink1), [FBXO7](/genes/fbxo7), and [VPS35](/genes/vps35) mutations further cemented the importance of UPS and related protein quality control pathways in PD pathogenesis [@kitada1998][@valente2004].
Early pathological studies demonstrated that ubiquitin-positive inclusions, particularly Lewy bodies, are a hallmark of PD brain tissue. These inclusions, composed primarily of misfolded alpha-synuclein, are extensively ubiquitinated, indicating failed attempts by the UPS to clear these toxic species [@shojaee2008]. The presence of ubiquitinated proteins in Lewy bodies provided direct pathological evidence of UPS impairment in PD.
The UPS consists of two key degradation pathways working in concert to maintain cellular proteostasis:
Ubiquitin-Activating Enzymes (E1)
The ubiquitin cascade begins with E1 enzymes that activate ubiquitin in an ATP-dependent manner. The human genome encodes approximately 10 E1 enzymes that serve as the entry point for ubiquitin conjugation. These enzymes form a thioester bond between the C-terminal glycine of ubiquitin and a cysteine residue on the E1 enzyme, preparing ubiquitin for transfer to E2 enzymes [@zimprich2011].
Ubiquitin-Conjugating Enzymes (E2)
Over 30 E2 enzymes in humans receive ubiquitin from E1 enzymes and catalyze its transfer to substrate proteins. E2 enzymes determine the type of ubiquitin chain formed, which in turn dictates the fate of the modified protein. Different E2s generate different linkages (K48, K63, K27, K6, etc.) that serve distinct cellular functions ranging from proteasomal degradation to signaling and DNA repair [@mcgeer2003].
Ubiquitin Ligases (E3)
The substrate specificity of the UPS is determined by approximately 600 E3 ubiquitin ligases in humans. These enzymes recognize specific substrates and facilitate ubiquitin transfer from E2 to target proteins. E3 ligases are classified into two major families: RING (Really Interesting New Gene) finger E3s that function as scaffolds bringing E2 and substrate together, and HECT (Homologous to E6-AP C-terminus) E3s that form a thioester intermediate with ubiquitin before transferring it to the substrate [@grune2004].
The Proteasome
The 26S proteasome is a large ATP-dependent protease complex composed of two substructures: the 20S core particle (CP) and the 19S regulatory particle (RP). The 20S CP is a barrel-shaped structure formed by four stacked heptameric rings (two alpha and two beta) that contains the proteolytic active sites within its interior. The 19S RP binds to the alpha rings of the 20S CP, recognizes ubiquitinated substrates, removes the ubiquitin chain, unfolds the substrate, and translocates it into the proteolytic chamber [@zhang2005].
Ubiquitination is a reversible post-translational modification involving the covalent attachment of ubiquitin to target proteins. This process regulates numerous cellular processes including protein degradation, signal transduction, DNA repair, and membrane trafficking. In protein quality control, ubiquitination serves as a molecular tag marking damaged, misfolded, or obsolete proteins for degradation by the proteasome or [autophagy](/entities/autophagy)-lysosome system [@rott2009].
The complexity of ubiquitin signaling arises from the ability to form different types of ubiquitin chains. Lysine 48 (K48)-linked chains are the canonical signal for proteasomal degradation, while Lysine 63 (K63)-linked chains regulate signaling pathways, endocytosis, and autophagy. Monoubiquitination and branched chains add further layers of regulation to cellular processes.
Parkin Mutations and Loss of Function
Parkin (encoded by PARK2) is an E3 ubiquitin ligase that plays critical roles in mitochondrial quality control through mitophagy [@ebrahimifakhari2011]. Over 200 pathogenic mutations in PARK2 have been identified in patients with autosomal recessive juvenile-onset Parkinson's disease. These mutations result in loss of parkin function, leading to impaired clearance of damaged mitochondria and accumulation of toxic proteins [@matsuda2009].
Parkin substrates include mitochondrial proteins, synaptic proteins, and cell cycle regulators. The inability to ubiquitinate these substrates leads to their accumulation and toxicity. Key parkin substrates include Mitofusin-1 and Mitofusin-2 (mitochondrial outer membrane proteins involved in fusion), VDAC1 (voltage-dependent anion channel 1 involved in mitochondrial permeability), Synphilin-1 (an alpha-synuclein-interacting protein found in Lewy bodies), and Cyclin E (cell cycle regulator) [@kane2014].
PINK1 Kinase Dysfunction
PINK1 (PTEN-induced kinase 1) is a mitochondrial serine/threonine-protein kinase that activates parkin by phosphorylating both parkin and ubiquitin at specific residues [@durcan2014]. PINK1 accumulates on the outer membrane of damaged mitochondria, where it phosphorylates ubiquitin and parkin to initiate mitophagy. Mutations in PINK1 cause autosomal recessive Parkinson's disease, typically with earlier onset than parkin mutations.
The PINK1-parkin pathway represents a critical mitochondrial quality control mechanism. Under basal conditions, PINK1 is imported into mitochondria and degraded. Upon mitochondrial damage, PINK1 stabilization on the outer membrane triggers parkin recruitment and activation, leading to ubiquitination of mitochondrial outer membrane proteins and selective autophagy of the damaged organelle [@sullivan2021].
FBXO7 Mutations
FBXO7 (F-box only protein 7) is a component of SCF (Skp1-Cul1-F-box) ubiquitin ligase complexes. Mutations in FBXO7 cause PARK15, a form of early-onset Parkinson's disease with pyramidal tract involvement [@tanaka2010]. FBXO7 interacts with parkin and PINK1, suggesting it functions in the same mitochondrial quality control pathway. FBXO7 deficiency leads to impaired mitophagy and accumulation of damaged mitochondria.
VPS35 and Retromer Dysfunction
VPS35 is a core component of the retromer complex that mediates cargo sorting from endosomes to the trans-Golgi network and plasma membrane. The VPS35 D620N mutation causes autosomal dominant late-onset Parkinson's disease [@ofarrell2014]. Retromer dysfunction impairs trafficking of proteins including the cation-independent mannose-6-phosphate receptor and [APP](/entities/app-protein) (amyloid precursor protein), linking VPS35 mutations to lysosomal dysfunction and protein aggregation.
Proteasomal Impairment in Sporadic PD
Beyond genetic forms, sporadic PD is associated with acquired proteasome impairment. Multiple mechanisms contribute to reduced proteasome activity in PD brain:
| Protein/Gene | Role in UPS Dysfunction | PD Type |
|--------------|------------------------|---------|
| [PARK2/parkin](/genes/parkin) | E3 ubiquitin ligase, mitophagy receptor | Familial (AR) |
| [PINK1](/genes/pink1) | Kinase that activates parkin | Familial (AR) |
| [FBXO7](/genes/fbxo7) | SCF ubiquitin ligase complex component | Familial (AR) |
| [VPS35](/genes/vps35) | Retromer subunit, protein trafficking | Familial (AD) |
| [UBE2A](/genes/ube2a) | Ubiquitin-conjugating enzyme | X-linked |
| [SUMO1](/genes/sumo1) | SUMOylation, protein degradation | Modifier |
| [UBB+1](/genes/ubb+1) | Mutant ubiquitin, proteasome inhibition | Sporadic |
| [BMP](/genes/bmp) | Proteasome assembly chaperone | Modifier |
Parkin Knockout Mice
Parkin-deficient mice do not develop spontaneous dopaminergic neuron loss, highlighting the complexity of PD pathogenesis and species differences in protein quality control requirements. However, these mice show increased sensitivity to mitochondrial toxins (MPTP, rotenone), altered dopamine metabolism, impairments in synaptic function, and behavioral phenotypes relevant to PD [@schwartz2020].
PINK1 Knockout Mice
Similar to parkin knockout mice, PINK1-deficient mice do not develop spontaneous neurodegeneration but show mitochondrial dysfunction in dopaminergic neurons, enhanced vulnerability to mitochondrial toxins, synaptic abnormalities, and locomotor deficits [@seifikar2022].
Double Knockout Models
Combined deficiency of parkin and PINK1 in mice produces more severe phenotypes than single knockouts, suggesting overlapping and compensatory functions. These models demonstrate that loss of mitophagy alone is insufficient to cause neurodegeneration, indicating additional factors are required.
Proteasome Inhibitor Models
Administration of proteasome inhibitors (lactacystin, MG132) to rodents produces selective dopaminergic neuron loss in substantia nigra, alpha-synuclein aggregation, ubiquitin-positive inclusions, and motor deficits [@feng2019]. These models directly test the role of UPS impairment in PD pathogenesis and support the hypothesis that UPS dysfunction is sufficient to cause parkinsonism.
Cell culture models have been instrumental in understanding UPS dysfunction:
UPS dysfunction markers in cerebrospinal fluid (CSF) and blood have been investigated as potential biomarkers. Decreased proteasome activity in CSF correlates with disease severity, while elevated ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) in CSF and monoubiquitinated proteins in patient samples have been reported [@peterson2021]. However, these markers lack specificity for clinical diagnosis.
Assessment of proteasome activity in peripheral blood mononuclear cells (PBMCs) shows reduced activity in PD patients compared to healthy controls. This reduction correlates with disease duration and severity, suggesting potential as a progression marker. However, standardization between laboratories remains challenging.
Proteasome Activators
Multiple classes of proteasome activators are being developed including natural compounds (curcumin, resveratrol), synthetic small molecules (salinosporamide A derivatives), and peptide-based activators. The challenge lies in achieving sufficient brain penetration and targeting specific neuronal populations [@huang2023].
E3 Ligase Modulators
Targeting specific E3 ligases involved in PD includes parkin activators to enhance mitophagy, inhibitors of excessive E3 activity that may contribute to pathology, and modulators of parkin substrate specificity. Small molecules that stabilize parkin in its active conformation are under development [@riley2022].
Autophagy Enhancement
Since the UPS and autophagy are interconnected, autophagy enhancers may compensate for UPS impairment through [mTOR](/mechanisms/mtor-signaling-pathway) inhibitors (rapamycin, everolimus), natural autophagy inducers (trehalose, spermidine), and [TFEB](/entities/tfeb) (transcription factor EB) activators that promote lysosomal biogenesis [@decressac2020].
Antioxidant Therapies
Reducing oxidative damage to proteasome components includes mitochondrial-targeted antioxidants (MitoQ, MitoVitE), N-acetylcysteine and glutathione precursors, and coenzyme Q10 supplementation. These approaches address upstream causes of proteasome impairment rather than the impairment itself.
The UPS is regulated not only by E3 ligases but also by deubiquitinating enzymes (DUBs) that remove ubiquitin from substrates. Several DUBs are implicated in PD including UCHL1 (mutations cause PD; enzyme activity is reduced in sporadic PD), USP30 (regulates mitophagy by removing ubiquitin from mitochondrial proteins), and USP24 (genetic variant associated with PD risk) [@harrington2024].
The UPS does not function in isolation but is part of a larger proteostasis network including molecular chaperones (HSP70, HSP90), the autophagy-lysosome system, mitochondrial quality control, and ER-associated degradation (ERAD). Understanding how these systems interact and compensate for each other may reveal therapeutic targets. The proteostasis network becomes increasingly impaired with age, potentially explaining late-onset of sporadic PD [@klaips2024].
Alpha-synuclein pathology and UPS dysfunction have a bidirectional relationship. Mutant alpha-synuclein inhibits proteasome activity, UPS impairment promotes alpha-synuclein aggregation, and this creates a vicious cycle accelerating neurodegeneration. Breaking this cycle represents a key therapeutic strategy. Studies show that reducing alpha-synuclein burden through immunotherapy or gene silencing may restore UPS function [@wong2023].
Proteins that recognize specific ubiquitin modifications (ubiquitin readers) are increasingly implicated in PD. p62/SQSTM1, which recognizes K63-linked ubiquitin chains and targets proteins for autophagy, is found in Lewy bodies. TIA1, an RNA-binding protein that associates with stress granules, also localizes to protein inclusions in PD. These readers represent novel therapeutic targets [@guzman2024].
The PARK2 gene, encoding the parkin protein, was the first linked to autosomal recessive juvenile-onset Parkinson's disease. Over 200 pathogenic variants have been identified, including point mutations, deletions, and multiplications. Parkin mutations cause loss of E3 ligase activity, leading to impaired mitophagy and accumulation of toxic substrates [@luck2020].
PINK1 mutations account for approximately 1-2% of early-onset PD cases. Most mutations are loss-of-function, impairing the kinase's ability to activate parkin. Interestingly, some PINK1 mutations retain partial function, explaining the later onset compared to parkin mutations [@puschmann2019].
FBXO7 mutations cause a rare form of early-onset PD with pyramidal tract involvement. The clinical phenotype includes bradykinesia, rigidity, and spasticity, distinguishing it from typical PD. FBXO7's role in proteasomal degradation of substrates extends beyond mitochondrial quality control [@di2021].
The VPS35 D620N mutation is one of the few causes of autosomal dominant late-onset PD. Unlike other genetic forms that present before age 50, VPS35 carriers typically develop symptoms after age 50, more closely resembling sporadic PD. The retromer's role in protein trafficking links it to both UPS and lysosomal dysfunction [@chen2022].
In Alzheimer's disease (AD), UPS dysfunction contributes to [tau](/proteins/tau) and [amyloid-beta](/proteins/amyloid-beta) accumulation. Proteasome activity is reduced in AD brain, and tau oligomers can inhibit proteasome function. The relationship between amyloid pathology and UPS impairment is complex and bidirectional [@tai2023].
ALS features mutations in SOD1, [TDP-43](/mechanisms/tdp-43-proteinopathy), FUS, and [C9orf72](/entities/c9orf72). TDP-43 inclusions are ubiquitinated and may reflect failed UPS clearance. Proteasome activity is impaired in ALS models, and enhancing proteasome function has shown benefit in animal models [@bolognin2022].
Huntington's disease is caused by polyglutamine expansions in [huntingtin protein](/proteins/huntingtin). Mutant huntingtin impairs proteasome function through direct inhibition and transcriptional dysregulation of proteasome subunits. The UPS is overwhelmed by mutant huntingtin aggregates, making it a therapeutic target [@hipp2024].
Ubiquitin-proteasome system dysfunction is a central mechanism in Parkinson's disease pathogenesis, linking genetic mutations, environmental factors, and aging-related decline in protein quality control. The identification of mutations in UPS components (PARK2, PINK1, FBXO7, VPS35) in familial PD and the demonstration of acquired proteasome impairment in sporadic PD underscore the importance of this pathway. Therapeutic strategies targeting UPS dysfunction, either directly through proteasome activation or indirectly through enhancement of compensatory pathways, represent promising approaches for disease-modifying treatments in Parkinson's disease.